Epidemiological Risk Factors Associated with High Global Frequency of Inapparent Dengue Virus Infections by Laura Grange et al.
REVIEW ARTICLE
published: 11 June 2014
doi: 10.3389/fimmu.2014.00280
Epidemiological risk factors associated with high global
frequency of inapparent dengue virus infections
Laura Grange1,2, Etienne Simon-Loriere1,2, Anavaj Sakuntabhai 1,2, Lionel Gresh3, Richard Paul 1,2* and
Eva Harris4*
1 Unité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France
2 URA3012, Centre National de la Recherche Scientifique, Paris, France
3 Sustainable Sciences Institute, Managua, Nicaragua
4 Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, CA, USA
Edited by:
Scott B. Halstead, International
Vaccine Institute, South Korea
Reviewed by:
Dirk Dittmer, University of North
Carolina at Chapel Hill, USA
In-Kyu Yoon, U.S. Army, USA
*Correspondence:
Richard Paul , Unité de la Génétique
Fonctionnelle des Maladies
Infectieuses, Institut Pasteur, 28 rue
du Docteur Roux, F-75724 Paris
Cedex 15, France
e-mail: richard.paul@pasteur.fr ;
Eva Harris, Division of Infectious
Diseases and Vaccinology, School of
Public Health, University of California,
185 Li Ka Shing Center, 1951 Oxford
Street, Berkeley, CA 94720-3370,
USA
e-mail: eharris@berkeley.edu
Dengue is a major international public health concern, and the number of outbreaks has
escalated greatly. Human migration and international trade and travel are constantly intro-
ducing new vectors and pathogens into novel geographic areas. Of particular interest is
the extent to which dengue virus (DENV) infections are subclinical or inapparent. Not only
may such infections contribute to the global spread of DENV by human migration, but also
seroprevalence rates in naïve populations may be initially high despite minimal numbers
of detectable clinical cases. As the probability of severe disease is increased in secondary
infections, populations may thus be primed, with serious public health consequences fol-
lowing introduction of a new serotype. In addition, pre-existing immunity from inapparent
infections may affect vaccine uptake, and the ratio of clinically apparent to inapparent infec-
tion could affect the interpretation of vaccine trials. We performed a literature search for
inapparent DENV infections and provide an analytical review of their frequency and asso-
ciated risk factors. Inapparent rates were highly variable, but “inapparent” was the major
outcome of infection in all prospective studies. Differences in the epidemiological context
and type of surveillance account for much of the variability in inapparent infection rates.
However, one particular epidemiological pattern was shared by four longitudinal cohort stud-
ies: the rate of inapparent DENV infections was positively correlated with the incidence of
disease the previous year, strongly supporting an important role for short-term heterotypic
immunity in determining the outcome of infection. Primary and secondary infections were
equally likely to be inapparent. Knowledge of the extent to which viruses from inapparent
infections are transmissible to mosquitoes is urgently needed. Inapparent infections need
to be considered for their impact on disease severity, transmission dynamics, and vaccine
efficacy and uptake.
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INTRODUCTION
Dengue has become a major international public health concern
and is the most important arthropod-borne disease of humans (1–
4). Any of the four antigenically distinct viruses, or serotypes, des-
ignated dengue virus (DENV)-1, DENV-2, DENV-3, and DENV-4,
belonging to the Flavivirus genus in the family Flaviviridae, can
cause dengue fever (DF), an acute viral infection characterized
by fever, rash, headache, muscle and joint pain, and nausea, as
well as more severe forms of the disease. A possible fifth serotype
has recently been detected, but its global significance remains
to be seen (5). Occasionally, DF progresses to dengue hemor-
rhagic fever/dengue shock syndrome (DHF/DSS), a potentially
life-threatening illness associated with vascular leakage, hemor-
rhage, and shock. By contrast, it is increasingly recognized that the
majority of DENV infections are subclinical, resulting in insuf-
ficient discomfort for clinical consultation (6). This reservoir of
infection needs to be addressed.
Over the past decade, the number of dengue outbreaks has esca-
lated (4), and the population at risk is increasing yearly. More than
3.5 billion people are at risk of DENV infection. It has recently
been estimated that there are 390 million DENV infections every
year, of which up to 96 million are symptomatic (7). This prolific
increase has been associated with societal changes such as popula-
tion growth and increasing urbanization, particularly in tropical
cities with poor waste and water management, leading to prolif-
eration of the domestic and peridomestic mosquito species that
transmit DENV, Aedes aegypti and A. albopictus. Human migra-
tion and international trade and travel are constantly introducing
new vectors and pathogens into novel geographic areas (8, 9).
In addition, it has been suggested that rising temperatures and
global climate change may lead to the expansion of the range of
major mosquito vectors into new areas, extension of the trans-
mission season in areas with currently circulating DENV, decrease
in extrinsic incubation period, and increase in the mosquito spp.
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vectorial capacity (10, 11). The potential threat of DENV inva-
sion of continental Europe has recently been illustrated by cases of
autochthonous dengue in southern France (12). These cases bear
testament to the capacity of local A. albopictus mosquito vector to
transmit the virus. This Asian tiger mosquito is the major potential
vector of DENV in Europe, although the most important vector
world-wide, A. aegypti, was identified in Madeira Island, Portugal,
in October 2005. A major epidemic occurred in Madeira in 2012
(13). Autochthonous transmission of DENV in the United States
has also been reported intermittently over the past decade in Texas,
Hawaii, and Florida (14, 15).
International travel will ensure importation of virus into non-
endemic countries from regions endemic for dengue. Infected
individuals may harbor sufficiently high viral loads to infect mos-
quitoes prior to the onset of symptoms and thereby introduce
the virus into the population. Potentially more important is the
epidemiological significance of inapparent, subclinical infections.
Travelers may import virus without showing overt clinical symp-
toms and thus will not be detectable either in the airports or once
in the country. There is some suggestion that primary (1°) DENV
infections can be majoritarily inapparent in certain outbreaks (16),
whereas secondary (2°) infections lead to more severe symptoms
even when occurring 20 years later (17). In fact, the longer the
interval between heterotypic DENV infections, the higher the
case fatality rate (18). The public health consequences of such
inapparent infections are considerable, because apparently naïve
populations may well have been previously exposed to infections,
and once hospital cases of dengue are detected, the population as a
whole may have already been primed with prior DENV infection.
The frequency of inapparent infections is extremely variable
year to year, the risk factors poorly understood, and the terminol-
ogy not standardized. Subclinical, inapparent, and asymptomatic
infections are often used as synonyms, and the use of paucisymp-
tomatic is used to designate a DENV infection with few symptoms.
We will use subclinical and inapparent to denote infections with
insufficient symptoms to be detected by the research or national
surveillance program and/or to incite the infected individual to
consult, but for which there is evidence, either by seroconversion
or detection of virus, that the individual was infected with DENV.
Asymptomatic infections will be used when there are no symp-
toms at all reported by the infected individual during an active
infection, whether inferred by seroconversion or serology.
We review the literature on the extent of inapparent DENV
infections, identify associated risk factors, and highlight sev-
eral important lacunae that need to be addressed to assess the
extent of the epidemiological importance of inapparent infec-
tions. We combine a PubMed literature search approach with
review of articles cited within PubMed hits, plus a review of the
classical pre-PubMed dengue literature. The search strategy was
dengue+ one of the following: inapparent, asymptomtic, subclin-
ical. This search (27 January 2014) yielded 28, 151, and 34 articles,
respectively. Acceptance criteria for selection were: (i) definition
of symptom classification, (ii) ascertainment of symptoms and
recent/concurrent viral infection at an individual level, and (iii)
quantification of the number of inapparent infections. Of the
retrieved PubMed articles, 33 publications fulfilled the acceptance
criteria (19–51). An additional 14 articles cited within the above
fulfilled acceptance criteria (52–65). One further recent article was
known to the authors (66). A short description of each study is
presented in the Supplementary Material and in Table 1. Below,
we highlight features pertinent to dengue epidemiology that these
studies elucidate.
RETROSPECTIVE AND OUTBREAK STUDIES
There were 12 retrospective or outbreak studies with measures of
seropositivity and subjective recollection of fever and/or dengue-
associated symptoms (Australia 1, British Virgin Islands 1, Colom-
bia 1, Cuba 2, Puerto Rico 2, Brazil 2, South Pacific 1, Singapore
1, and Taiwan 1) (19–25, 53–57). In Cuba, the inapparent rate
during the 1981 DENV-2 epidemic was estimated to be 71% in
whites and 88% in blacks; the infections were considered likely to
be 2°, as 45% of the population was thought to have seroconverted
during the 1977 DENV-1 epidemic (54). During the 1997 Cuban
DENV-2 epidemic, all 2° infections were clinically overt, but only
3–6% of 1° infections were apparent (55). In the Brazilian studies,
inapparent rates were 27 and 53% in 1° infections vs. 37 and 39%
in 2° infections (22, 23). In Colombia, repeated cross-sectional
studies were carried out over a period of 17 months; 259 of 3,189
individuals showed clinical signs of viral infection and/or anti-
DENV IgM antibodies; 86% were inapparent (24). In the Puerto
Rican studies, where infections were majoritarily 1°, inapparent
rates were 53 and 43% (56, 57). The Singapore and South Pacific
studies were carried out during the epidemic period, and inap-
parent rates of 78 and 60% were reported, respectively (25, 53).
The Australian study was performed in 1995 to address the 1993
DENV epidemic; only 11% of infections were considered to be
inapparent (19). Longer-term recollection of 1° infections in indi-
viduals hospitalized in Taiwan with 2° infections suggested that
80% of 1° infections had been inapparent (21). Finally, return-
ing US volunteers from the British Virgin Islands in a community
with a suspected dengue case revealed that all DENV IgM-positive
individuals had recollection of symptoms (20).
NON-RESIDENTS (EXPATS, MILITARY, AND TRAVELERS)
Nine prospective studies were identified involving expats, travel-
ers, or military personnel staying in dengue-endemic areas (Haiti
1, Singapore 1, Somalia 1, Thailand 2, various 4) (48–51, 61–65).
Seroconversion rates were low, yielding relatively few infections
in any study. In the majority of studies, symptomatic infections
referred to the occurrence of any dengue-like symptom. Sharp et al.
(62) and Cobelens et al. (49) defined a symptomatic infection as
fever plus any other symptom. Baaten et al. (50) obtained objective
measure of fever or any other symptoms for defining symptomatic
DENV infections (50). For the majority of individuals, the infec-
tion was considered to be their first, and the inapparent rate ranged
from 0 to 100%. The majority (80–100%) of Americans (61) and
Japanese (48) in Thailand had symptoms, whereas no Australian
travelers to Asia reported symptoms (51). Sixty to 80% of Dutch
travelers (world-wide) reported no symptoms (49, 50), whereas
50% of Israeli travelers had symptoms (63). Over 90% of Chi-
nese workers experienced symptoms in Singapore (64), 85% of
American military personnel had symptoms in Somalia (62), and
all seven missionaries who were seropositive for DENV returning
from Haiti reported dengue-like symptoms (65).
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Table 1 | Prospective studies addressing the inapparent rate.
Place and
reference
Virus (years) Minimum
symptom
% Inapparent
(N )
Incidence rate:
disease; infection
Age (years) Seroprevalence
Puerto Rico (58) DENV-4 (1982) Fever 45 (56) 36%; 31% All 70%
Nicaragua (59) DENV-1 and DENV-2
(2001–2003)
Fever 91 (106) 8.3–8.5/1000;
6–12%
4–16 91%
Nicaragua
(39, 41, 42)
DENV-1 (2004–2005); DENV-2
(2006–2008); DENV-3
(2008–2010)
Fever or WHO 83 (1778) 3.4–43.5; 67–110
(/1000 person-years)
2–14 30% age 2; 90%
age 9
Nicaragua (40) DENV-2 (2006–2007) Any 42 (12) 0.2–1.4%; 7% 11–67 ND
Peru (52) DENV-1 and -2 (1999–2001);
DENV-3 (2002–2028); DENV-4
(2008–2011)
Fever 93 (3837) 0.5–19; 2–90 (/100
person-years)
All 60% age 2; 90%
age 15
Brazil (38) DENV-2 and DENV-3
(2007–2008)
Fever+ 2 WHO 77 (30) 2%; ND 1–79 56–77%
Thailand (26) DENV-1–4 (1980–1981) Fever 87 (103) 0.74%; 5.9% 4–16 39% 4–6 years;
73% 13–15 years
Thailand (27) DENV-1–4 (1998–1999) Fever 54 (331) 2.7%; 5.8% 7–11 ND
Thailand (30) DENV-1–4 (1998–2002) Fever 56 (569) 6.4%; 25.5% 7–15 ND
Thailand (45) DENV serotype not known
(2000–2001)
Fever 85 (34) 2; 7 (/100
person-years)
Birth – 8 ND
Thailand (32) DENV-4 (2004–2005) and
DENV-1 (2006–2007)
Fever 65 (535) 1.3–4.4%; 6.9% 4–15 ND
Fever or other 20 (119) 11.8%; 16%a 0.5–15
Thailand (29) DENV-4 (2004–2005) Fever 52 (27) 6.0%; 12.4%a 0.5–15 ND
Thailand (60) DENV-1 (2001) Clinical consultation 94 (54) 0.2%; 3.1% All 6%
Thailand (28) DENV-1 (2000–2001); DENV-2
(2002)
Clinical consultation 91 (733) 0.3%; 1–27% All ND
Vietnam (35) DENV-2 (2004–2005); DENV-1
(2006–2007)
Fever ≥38° for
≥2 days
80 (953) 17–40/1000; 8–14% 2–15 20–29%
Vietnam (44) DENV-1 dominant Fever 90 (10) 0.2; 1.7 (/100
person-years)
Birth – 2 ND
Indonesia (37) DENV-1–4 (2001–2003) Fever 47 (17) 1.5%; 2.5% All ND
Indonesia (36) DENV-1–4 (2000–2002) Any 75 (74) 18; 74 (/1000
person-years)
18–66 ND
Philippines
(46, 47)
DENV-3 and DENV-2
(2007–2009)
Clinical consultation 90 (115) 8–16; 103 (/1000
person-years)
Birth – 1 ND
Multi-centric (43) DENV-1, -2, -3 (2006–2007)
Southeast Asia
Fever 85 (20) Southeast
Asia
0.9%; 6.1%b >24 months ND
DENV-1, -3 (2006–2007) Latin
America
63.2 (19) Latin
America
8.3%; 22%b
aIndicates positive index clusters only; cluster contacts followed for 15 days or
b7 days.
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BIRTH COHORTS – MATERNAL ANTIBODY STUDIES
Four birth cohort studies addressed the potentially deleterious
effects of maternal antibody for outcome of DENV infection in
infants (Philippines 2,Vietnam 1, Thailand 1) (44–47). The occur-
rence of severe disease in infants following their first infection was
noted by Halstead and colleagues and contributed to the develop-
ment of the theory of antibody-dependent enhancement (ADE);
antibodies from a first infection are insufficient to neutralize
virus from a second infection of a different serotype and actually
increase virus internalization in Fcγ receptor-bearing target cells
and hence viremia (67). In infants, following a period of protec-
tion by maternally acquired anti-DENV antibodies, catabolism of
these antibodies was hypothesized to decrease the titer of mater-
nally acquired antibodies to enhancing levels and thus lead to
the high incidence of severe dengue disease observed in infants
(68). The birth cohort studies did not confirm the ADE hypoth-
esis, although samples sizes were small. The inapparent DENV
infection rate ranged from 75 to 90%.
PROSPECTIVE STUDIES
Twenty-three published papers describe analyses of prospective
studies carried out in Southeast Asia (Thailand 10, Vietnam 1,
Indonesia 2) (26–37, 60) and the Americas (Brazil 1, Nicaragua
5, Peru 2, Puerto Rico 1) (38–42, 52, 58, 59, 66) and one multi-
center study covering Vietnam, Cambodia, French Guiana, and
Brazil (43). The Thai studies occurred in one of three sites
(Bangkok, Chang Mai, or Kamphaeng Phet); the Nicaragua, Peru,
and Indonesia studies occurred in Managua, Iquitos, and Jakarta,
respectively. The studies used one or more of several protocols:
community-based cohort with paired healthy samples and labo-
ratory work-up of suspected dengue cases/undifferentiated febrile
illnesses, follow-up of school-based absenteeism, and index cluster
analysis. Anti-DENV antibodies were detected using rapid diag-
nostic kits, in-house ELISA assays, hemagglutination inhibition
assay, and/or neutralizing antibody tests. The age group sampled
varied considerably, as did the seroprevalence and force of infec-
tion. Notably, although the majority of studies focused on children
or the general community, one of the Indonesian studies targeted
an adult cohort (36). The classification of a symptomatic DENV
infection varied from the presence of any symptom, to just fever
or fever plus two additional dengue-associated symptoms accord-
ing to the WHO case definition. The inapparent DENV infection
rate ranged from 20 to 97%; the weighted mean inapparent rates
of cluster and cohort studies were 37 and 76% respectively. Mean
inapparent rates in cohort studies were 77.1% in the Americas and
74.4% in Asia.
EXPERIMENTAL INOCULATIONS (Pre-1960s)
The experimental infection studies in the first half of the twenti-
eth century provide the foundations of our current knowledge of
dengue (69,70). Siler et al. (69) conducted a series of induced infec-
tion experiments in military personnel using infected mosquitoes.
Of 47 subjects, four individuals remained refractory to infection
(or were asymptomatic) and two had very mild symptoms. The
inclusion criteria aimed to recruit individuals who were naïve to
dengue, but it could not be ruled out that some individuals had
been previously exposed to DENV. Thus, assuming no immunity,
the inapparent rate was at most 13% (6/47).
Simmons et al. (70) gave detailed accounts of the course and
outcome of infection using mosquito-induced infections in Amer-
ican military personnel, residents of the Philippines, monkeys,
and other animals (70). All 81 infections induced using com-
petent species of mosquitoes (A. aegypti, A. albopictus) after an
appropriate extrinsic incubation period (>9 days) yielded DF;
only 13.6% were classified as mild (undefined). The extent of
asymptomatic or even inapparent infections was clearly very low
in American military personnel with no likely previous exposure
to dengue. Adult Philippine individuals living in endemic zones
for dengue proved immune, whereas those from non-endemic
areas proved susceptible and were symptomatic following DENV
infection. Successful experimental infections without symptoms in
naïve Macaque monkeys were achieved, as demonstrated through
onward transmission to mosquitoes. Although such onward trans-
mission studies were not carried out in purportedly unsuccessful
DENV-induced infections in humans, the authors state “In addi-
tion, it is quite probable that mild unrecognizable infections may
occur in many adults, as has been proved possible in monkeys, and
that virus can be transmitted from these apparently symptomless
cases of dengue.”
POTENTIAL EXPLANATIONS FOR DIFFERENCES IN
OBSERVED INAPPARENT RATES
DETECTION METHODOLOGY
Retrospective surveys involving questionnaires of perceived symp-
toms are open to perception bias as well as the non-specificity of
dengue symptoms. Prospective studies use varying definitions of
a symptomatic dengue episode and different protocols for case
detection that generate considerable variation in inapparent infec-
tion rates. This is particularly well demonstrated by two alternative
protocols implemented in the same population: the index cluster
approach revealed that many inapparent infections, as defined by
school absenteeism and passive case detection, had fever or other
symptoms (32). In addition to the increased case detection sen-
sitivity of the index cluster approach, such an approach may also
suffer from ascertainment bias: viruses responsible for index cases
identified by clinical presentation may be more pathogenic and
thus lead to increased symptomatic infections in the clusters than
would occur in the general population. However, symptomatic
cases in clusters were found to be milder than those in the cohort
study (33).
INFLUENCE OF HUMAN GENETICS
A broad overview of global incidence of disease attributable to
dengue suggests that disease severity is greater in Southeast Asia
than in the Americas and that severe dengue is infrequent in Africa
(71). One major confounding factor is separating geography and
the environment from ethnicity. However, the dengue epidemics
in Cuba have given support to the hypothesis that individuals
of African ethnicity are less susceptible to disease than white Cau-
casians (54). There is increasing evidence from candidate gene and
genome-wide studies that human genetics play a role in the out-
come of infection (72–74). Only one study, however, has attempted
to assess the impact of human genetics on inapparent outcome
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of infection. A polymorphism in the FcγRIIA was found to be
associated with inapparent infection vs. DF or DHF in the Cuban
population (75). In light of the epidemiological observations on
the global variation in the incidence of DENV infection and severe
disease, it seems likely that at least some of the observed variation
in the inapparent rate is attributable to human genetics.
PRIMARY VS. SECONDARY VS. POST-SECONDARY INFECTIONS
Secondary infections are considered to result in more severe out-
come of infection, due to the phenomenon of ADE and/or cross-
reactive T cells (67). Very little, however, is known specifically
about the impact of previous exposure to two serotypes on the
outcome of infection with a third serotype. A cohort study in
Brazil found that there were significantly more inapparent infec-
tions in 1° as compared to 2° infections (22). Olkowski et al. (66)
found that in Peru there was a reduction in symptomatic outcome
in post-secondary infections compared with 1° and 2° infections
as defined by pre-infection serological profile; 93% reduction in
symptomatic outcome for DENV-3 and a 64% reduction in dis-
ease outcome for DENV-4 (66). However, Montoya et al. (42)
found no differences in inapparent infection rates in first, second,
third, or even post-secondary infections in Nicaragua (42). Sev-
eral studies measuring the inapparent rate also evaluated whether
the observed infection was 1° or 2°(22, 23, 26, 29, 32, 38, 39, 42,
43, 52, 59). A mixed model logistic univariate regression revealed
that although there were significant differences in inapparent rate
among studies, there was no significant difference within study
site between the inapparent rate in 1° and 2° infections (Wald’s
χ21 = 0.27, P = 0.61) (Figure 1). Too few studies have been able to
address post-secondary (third or fourth) infections and infection
outcome for any meta-analysis to be performed.
SHORT-TERM CROSS-PROTECTIVE IMMUNITY
Sabin set the foundations for our current appreciation of acquired
immunity to dengue and the extent of cross-immunity (76). Three
important results arising from these early studies are of pertinence
here: (i) there exists a minimum infective dose, which could lead
to no symptoms but partial immunity; (ii) immunity to a recent
previous infection alters the outcome of a subsequent infection;
and (iii) virus attenuated via mouse passage yields symptom-
less infections that are transmissible to mosquitoes, albeit poorly
so. For cross-immunity, active immune protection was achieved
for up to 2 months, slight malaise/fever occurred in 2° infec-
tions 2–3 months later, and even after 9 months, dengue episodes
were milder. DENV infection and onward transmission to mos-
quitoes was demonstrated in 2° infections at 2–3 months and
9 months post-1° infection. Recent statistical and theoretical mod-
eling approaches lend support to Sabin’s demonstration that there
exists cross-serotype non-sterilizing immunity resulting in milder
clinical symptoms that may last for up to 2 years (77–79).
Endy et al. (30) first noted a significant impact of the previous
year’s dengue incidence on the inapparent rate; a high incidence
the previous year increased the current year’s inapparent rate. This
was proposed to be a result of heterotypic cross-immunity, as
described above. A plot of the inapparent rate against previous
dengue incidence reported in the longitudinal cohorts with suffi-
cient data (Nicaragua, Peru, Thailand, and Vietnam) (30, 35, 39,
41, 42, 52), all show the same positive relationship between the
incidence of infection the previous year and the inapparent rate in
the current year (Figure 2). However, the strength of the relation-
ship seems proportional to the seroprevalence. In Nicaragua and
Peru, the seroprevalence in the population was high, with most
children having been exposed to at least one serotype by 10 years
FIGURE 1 |The inapparent rate of primary and secondary DENV
infections within the same study site for Nicaragua (39, 41, 42, 59),
Thailand (26, 29, 32), Brazil (22, 23, 38), Peru (52), French Guiana,
Cambodia, andVietnam (43). Shown are means and 95% binomial
confidence intervals. Superimposed is the line of equality where the
inapparent rate of 2° infections equals that of 1° infections. • Nicaragua,
 Vietnam, + Cambodia, × Brazil, ♦ Peru,  French Guiana,
MThailand.
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FIGURE 2 |The relationship between the inapparent infection rate and DENV infection intensity the previous year. Linear trend lines were fitted.
(A) Nicaragua (39, 41) R2 = 0.43; (B) Peru (52) R2 =0.477. (C) Vietnam (35) R2 =0.20; (D)Thailand (30) R2 =0.21.
of age. In Vietnam, by contrast, the seroprevalence was lower for
the same age group (35). The correlation of the incidence of infec-
tion the previous year and the inapparent rate in the current year
are strongest for areas of higher seroprevalence and thus where
the majority of new infections are 2°. It is notable that the pos-
itive relationship for inapparent rate and previous year DENV
incidence of infection was significantly stronger when consider-
ing incidence of disease the previous year (R2= 0.76) rather than
infection (R2= 0.2) in the Vietnam cohort. This raises the ques-
tion of whether the acquired immune response is stronger when
infection is accompanied by disease, rather than being asympto-
matic; this has previously been observed in Japanese Encephalitis
(quoted in Barnes and Rosen) (53).
Of key importance is to ascertain whether the inapparent rate
is indeed driven by heterotypic immunity. The Nicaraguan Pedi-
atric Dengue Cohort Study throws some light on the question,
differentiating 1° from 2° infections (39). A reduced symptoma-
tology in the outcome of infection through heterotypic immunity
would only apply to 2° infections. The fluctuations in the inter-
annual inapparent rate in 2° infections oscillated inversely with the
previous years’ incidence rate, ranging from 67 to 97% and signifi-
cantly so with non-overlapping 95% binomial confidence intervals
(CIs) (calculated as inapparent/total infections) (Figure 3B). By
contrast, although the same oscillating inter-annual pattern was
observable in 1° infections, for which cross-protective immunity
is not relevant, the fluctuations were dampened, ranging from
82 to 92%, with overlapping 95% CIs (Figure 3A). This gives
credence to the hypothesis that short-term cross-protective immu-
nity plays a significant role in determining infection outcome in
2° infections.
More recently, several studies have analyzed the importance
of the time interval between successive DENV infections on the
outcome of infection in first, second, and post-2° infections. In
the Nicaragua cohort, Montoya et al. (42) found that the time
interval between successive first and second infections leading to
an inapparent second infection outcome was significantly shorter
(1.8 years) than that leading to a symptomatic infection outcome
(2.6 years) (42). There was no impact of time interval for post-
2° infections. In Thai cohorts, Anderson et al. (34) found similar
results; there was a higher probability of an infection being inap-
parent in 2° infections if occurring within 1.4 years of a previous
(thus 1°) infection; the time interval between infections leading to
DF or DHF was longer, at 1.9 and 2.6 years respectively, although
the number of DHF was small (34). Again there was no difference
for post-2° infections.
IMPACT OF THE CURRENT YEAR’S INCIDENCE
Endy et al. (30) also noted a significant negative impact of the
current year’s dengue incidence on the inapparent rate; a high
concurrent incidence reduced the inapparent infection rate (30).
This relationship was confirmed in the same cohort (R2= 1) (32),
but to a much lesser extent in both the Nicaraguan and Vietnamese
studies (R2= 0.12 and 0.23, respectively) (35, 39). There was no
relationship in the Peruvian study (R2= 0.07) (52). Careful studies
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FIGURE 3 |The proportion of (A) 1° and (B) 2° infections in the
Nicaraguan Pediatric Dengue Cohort Study (39) that was inapparent.
Shown are the proportions and the 95% binomial confidence intervals.
taking into account the force of infection in relation to inapparent
and symptomatic infection are needed.
The interplay between short-term cross-protective immunity
and spread of a novel serotype will lead to inapparent rates that will
depend on the historical prevalence of dengue (thus, the extent of
2° infections), the recent incidence of dengue (cross-protection),
and the nature of the virus itself. By example, in the Nicaraguan
cohort, the expansion of DENV-2 in 2005 (increasing from 20% of
infections to 53%) was accompanied by an increase in transmis-
sion intensity (8.6–11.1% incidence) and increase in symptomatic
outcome, particularly for 2° infections (3–25%) (39). This sug-
gests a classic reaction to a new serotype in a background primed
by other serotypes. The following year, transmission intensity
dropped (from 11.1 to 5.8%), there was an increase in the predom-
inance of DENV-2 (90% of all infections), and a decrease in rate
of symptomatic infections; this decrease was most dramatic for 2°
infections (25 to 4%), suggesting an important influence of cross-
protective immunity. Then, transmission intensity increased with
a concomitant rise in disease severity in both 1° and 2° infections.
The rise in disease severity despite no change in serotype would
suggest that the virus had evolved. Indeed, there was a clade change
in 2006 (from DENV-2 clade 1 to clade 2B), which was associated
with increased severity in the cohort and which could have con-
tributed to the final increase in severity of infection outcome (80).
Morrison et al. (52) proposed a three-step chronology for
the invasion of a novel serotype: amplification, replacement,
and epidemic (52). Implicitly underlying this chronology is the
notion of viral adaptation to its novel environment in competitive
circumstances. Viral evolution may also contribute to the rise in
the inapparent rate following the epidemic phase. Abortive dengue
epidemics, where the incidence of disease is low, have been noted
previously, and islands in the South Pacific have escaped severe
outbreaks occurring in their neighbors (53, 81).
VIRAL GENETICS
The importance of viral genetics in determining the outcome of
infection has been suggested in the context of 1° vs. 2° infections
(82), severe primary epidemics in naïve populations (53,81),mole-
cular variants yielding high replication rates in the laboratory (83),
DENV serotype, genotype, and clade, sequential order of serotypes
in infections (84), and interaction with pre-existing serotype-
specific immunity (80, 85). However, there is no consistent pattern.
Whilst confounding factors influence the disease severity of an epi-
demic, the genetic diversity of the viruses likely plays an important
role. As with all arboviruses, the RNA-dependent RNA poly-
merase’s lack of proofreading activity coupled with the large virus
population sizes lead to the constant generation of variants. This
means that RNA viruses generally circulate as dynamic mutant
networks (86). Recent studies reveal that DENV exist as heteroge-
neous populations in patients and mosquito vectors (87–93), but
the significance of this is unclear. Coupled to the selective forces
in both host and vector, these features would enable the circulat-
ing viral population to change significantly even during the course
of a single epidemic. Indeed, the proportion of severe cases has
been reported to increase toward the end of an outbreak (94–96).
Endy et al. (27) also noted that symptomatic cases extended later
into the season than inapparent infections (27). DENV popula-
tions may also rapidly change because of periodic selective sweeps
and by intra-serotypic recombination (97, 98), though this lat-
ter remains contentious. DENV infection leads to a spectrum of
outcome severity from inapparent to mild or severe disease; small
changes in viral genetics could lead to significant changes in infec-
tion outcome. However, despite increasing evidence for a role of
viral genetics in the outcome of infection, to date we do not know
the extent to which the observed variation in the inapparent rate
is influenced by viral diversity and evolution.
Genetic variation has been associated with differences in virus
transmission efficiency (99, 100). Viral adaptation during its inva-
sion phase may improve transmission capacity to mosquitoes
responsible for an epidemic and/or result in strains that are
responsible for more severe cases toward the end of the epidemic.
Infectiousness to mosquito increases with viremia and although
hospitalized cases have higher viremia, symptomatic but ambu-
latory cases infected mosquitoes equally well (101). Currently,
we have no knowledge about the comparative transmissibility of
inapparent infections, a crucial element that needs to be addressed.
CONCLUSION AND IMPLICATIONS
Establishing risk factors and the extent to which DENV infections
are inapparent is important not only for assessing whether there
will be a silent invasion of DENV into hitherto unaffected areas but
also for improving our understanding of dengue epidemiology and
infection severity. The epidemiological evidence to date suggests
that whilst the majority of infections are inapparent in endemic
settings, there are recognizable patterns that are consistent with an
important role for short-term heterotypic non-sterilizing immu-
nity. However, similar inter-annual fluctuations in the inapparent
rate in 1° infections require additional explanations, potentially
suggesting a role for viral evolution. One intriguing avenue of
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research is the extent to which heterotypic immunity promotes
viral diversification. Likewise, it would be interesting to assess how
human genetics impacts upon infection outcome.
Extrapolating from endemic settings to an invasion scenario
may not be applicable, especially given the significant role seem-
ingly played by the immune response in 2° infections, whether
enhancing or protective. Retrospective serological surveys in
recent virgin soil epidemics, for example, in Madeira and Cape
Verde,would provide invaluable information on the extent of inap-
parent infections under such scenarios and give a better idea of
what to expect under invasion and hence how best to implement
surveillance and control efforts.
Finally, an appreciation of inapparent DENV infections is
important for both interpretation of vaccine trials and vaccine
uptake. It has been suggested that, in the light of the high inci-
dence of inapparent DENV infections, vaccine trials should con-
sider other measures of vaccine efficacy in addition to occurrence
of clinically apparent infections, i.e., to consider efficacy against
infection and not just disease (102). Moreover, pre-existing immu-
nity from prior symptomatic and inapparent DENV infections will
likely affect the type of immunity induced by tetravalent vaccines
(i.e., homotypic vs. heterotypic), and this needs to be considered
as well. Lastly, successful vaccination should reduce the large reser-
voir of inapparent infections that are likely capable of onwardly
transmitting the virus, thus further reducing DENV transmission.
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